Expertise in
8
conditions

Dr. David L. Fried

Internal Medicine
Office
1575 S County Trl, 
East Greenwich, RI 
Offers Telehealth
Before you request
Expertise in
8
conditions
Office
1575 S County Trl, 
East Greenwich, RI 

Overview

David Fried is a primary care provider, practicing in Internal Medicine in East Greenwich, Rhode Island.

Dr. Fried is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and High Cholesterol.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 15 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in RI

Hospital Affiliations

Rhode Island Hospital
Newport Hospital
South County Hospital Inc
Kent County Memorial Hospital
The Miriam Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Office
1575 S County Trl, East Greenwich, RI 02818

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Terminated
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Terminated
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drug: Galcanezumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
View 9 Less Clinical Trials

5 Total Publications

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Journal: The New England journal of medicine
Published: April 08, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Christopher G. Azzoli
Internal Medicine
Expertise in
10
conditions
Dr. Christopher G. Azzoli
Internal Medicine

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (12.3 miles away)
401-444-5388
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Azzoli is a primary care provider, practicing in Internal Medicine in Providence, Rhode Island. Dr. Azzoli is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Before you request

Medical And Surgical Specialties

200 Boylston Street, 
Chestnut Hill, MA 
 (49.3 miles away)
617-632-8252
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adnan Majid is a primary care provider, practicing in Internal Medicine in Chestnut Hill, Massachusetts. Dr. Majid is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Tracheobronchomalacia, Acquired Tracheomalacia, Parapneumonic Pleural Effusion, Advanced Bronchoscopy, and Endoscopy. Dr. Majid is board certified in American Board Of Internal Medicine. Dr. Majid is currently accepting new patients.

Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Before you request

BIDMC - Division Of Gastroenterology/Liver Center

110 Francis Street, 
Boston, MA 
 (51.7 miles away)
617-632-1070
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Nezam Afdhal is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Afdhal is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Afdhal is currently accepting new patients.

Frequently Asked Questions about Dr. David L. Fried

How do I make an appointment with Dr. David L. Fried?

You can book an appointment with Dr. David L. Fried by calling their office at 401-884-0333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Fried a top-rated expert for Familial Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Fried is classified as an Advanced expert for Familial Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Fried specialize in?

While Dr. David L. Fried is a Internal Medicine, they have specific expertise in Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Hypertension. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David L. Fried participate in research or clinical trials?

Yes. Dr. David L. Fried has published 5 articles and abstracts on conditions like Familial Hypertension. You can view a list of Dr. David L. Fried's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David L. Fried accept my insurance?

Dr. David L. Fried accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 401-884-0333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fried's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 107 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile